Insulin Resistance and Diabetes Mellitus Associated With Antiretroviral Use in HIV-Infected Patients : Pathogenesis, Prevention, and Treatment OptionsTEBAS, Pablo.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, issn 1525-4135, S86-S92, SUP2Article

HIV and Cardiometabolic Abnormalities: New Perspectives and Treatment UpdateTEBAS, Pablo.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, issn 1525-4135, 29 p., SUP2Serial Issue

Is it time to rethink the expanded-access programs for HIV infection?AMOROSA, Valerianna; TEBAS, Pablo.The Journal of infectious diseases. 2007, Vol 196, Num 7, pp 974-977, issn 0022-1899, 4 p.Article

HIV and Antiretroviral Therapy : Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected PatientsKOTLER, Donald P.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, issn 1525-4135, S79-S85, SUP2Article

Bone disease and HIV infectionAMOROSA, Valerianna; TEBAS, Pablo.Clinical infectious diseases. 2006, Vol 42, Num 1, pp 108-114, issn 1058-4838, 7 p.Article

Management of Morphologic Changes Associated With Antiretroviral Use in HIV-Infected PatientsWOHL, David Alain; BROWN, Todd T.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, issn 1525-4135, S93-S100, SUP2Article

Emerging bone problems in patients infected with human immunodeficiency virusMONDY, Kristin; TEBAS, Pablo.Clinical infectious diseases. 2003, Vol 36, pp S101-S105, issn 1058-4838, SUP2Article

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsBEDIMO, Roger; MAALOUF, Naim M; SONG ZHANG et al.AIDS (London). 2012, Vol 26, Num 7, pp 825-831, issn 0269-9370, 7 p.Article

Seroprotection of HIV-Infected Subjects After Influenza A(H1N1) Vaccination Is Directly Associated With Baseline Frequency of Naive T CellsRAMIREZ, Lorenzo A; DANIEL, Alexander; FRANK, Ian et al.The Journal of infectious diseases. 2014, Vol 210, Num 4, pp 646-650, issn 0022-1899, 5 p.Article

Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy EraBEDIMO, Roger J; WESTFALL, Andrew O; DRECHSLER, Henning et al.Clinical infectious diseases. 2011, Vol 53, Num 1, pp 84-91, issn 1058-4838, 8 p.Article

Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapyTEBAS, Pablo; HENRY, Keith; NEASE, Robert et al.AIDS (London). 2001, Vol 15, Num 5, pp 591-599, issn 0269-9370Article

Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA IntegrationAZZONI, Livio; FOULKES, Andrea S; DEEKS, Steven G et al.The Journal of infectious diseases. 2013, Vol 207, Num 2, pp 213-222, issn 0022-1899, 10 p.Article

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsNELSON, Mark; AMAYA, Gerardo; VANVEGGEL, Simon et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, issn 0305-7453, 9 p.Article

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 WeeksABERG, Judith A; TEBAS, Pablo; TURNER OVERTON, Edgar et al.AIDS research and human retroviruses. 2012, Vol 28, Num 10, pp 1184-1195, issn 0889-2229, 12 p.Article

Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected IndividualsKRISHNAN, Supriya; SCHOUTEN, Jeffrey T; CAMPBELL, Thomas B et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 3, pp 381-389, issn 1525-4135, 9 p.Article

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224sMCCOMSEY, Grace A; KITCH, Douglas; SAX, Paul E et al.Clinical infectious diseases. 2011, Vol 53, Num 2, pp 185-196, issn 1058-4838, 12 p.Article

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenFISCHL, Margaret A; COLLIER, Ann C; BASSETT, Roland et al.AIDS (London). 2007, Vol 21, Num 3, pp 325-333, issn 0269-9370, 9 p.Article

Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapyGERBER, Marisa T; MONDY, Kristin E; YARASHESKI, Kevin E et al.Clinical infectious diseases. 2004, Vol 39, Num 3, pp 419-425, issn 1058-4838, 7 p.Article

Effect of prolonged discontinuation of successful antiretroviral therapy on CD⁴+ T cell decline in human immunodeficiency virus-infected patients: Implications for intermittent therapeutic strategiesTEBAS, Pablo; HENRY, Keith; MONDY, Kristin et al.The Journal of infectious diseases. 2002, Vol 186, Num 6, pp 851-854, issn 0022-1899, 4 p.Article

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialARRIBAS, Jose R; PIALOUX, Gilles; GATHE, Joseph et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 7, pp 581-589, issn 1473-3099, 9 p.Article

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 InfectionFÄTKENHEUER, Gerd; NELSON, Mark; BELLOS, Nicholaos et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1442-1455, issn 0028-4793, 14 p.Article

The Use of HAART Is Associated With Decreased Risk of Death During Initial Treatment of Cryptococcal Meningitis in Adults in BotswanaBISSON, Gregory P; NTHOBATSONG, Rudo; THAKUR, Rameshwari et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 2, pp 227-229, issn 1525-4135, 3 p.Article

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides : Dual X-ray absorptiometry results from A5005S, a substudy of adult clinical trials group 384DUBE, Michael P; KOMAROW, Lauren; MULLIGAN, Kathleen et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, Num 5, pp 508-514, issn 1525-4135, 7 p.Article

A pilot study evaluating time to CD4 T-Cell count <350 cells/mm³ after treatment interruption following antiretroviral therapy + interleukin 2 : Results of ACTG A5102HENRY, Keith; KATZENSTEIN, David; WINTERS, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 42, Num 2, pp 140-148, issn 1525-4135, 9 p.Article

Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trialMULLIGAN, Kathleen; PARKER, Robert A; KOMAROW, Lauren et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 41, Num 5, pp 590-597, issn 1525-4135, 8 p.Article